You will know about new technologies and person, who can revolutionize biology !

Vaxil Presents My Inventions As Vaxil’s Own

Alexander Cherkasky

alexcherkasky@googlemail.com

My published German patent application DE19951694 (from the year 1999
(Filing date: October 27, 1999)), which damages and claims priority
worldwide, discloses also in the claims 4 and 9 fusion proteins
comprising random proteins of interest and membrane penetration
domains (MPD) as well as fusion proteins comprising random proteins of
interest and signal peptides, i.e. signal peptide domains. Thus these
fusion proteins can migrate in extracellular and intracellular space
(claim 4).
This my invention of fusion proteins comprising any protein and signal
peptide domain, disclosed in DE19951694, was descibed and
plagiaristically used by the Israeli company Vaxil (by Lior Carmon) in
its US20120177677 (”Antigen Specific Multi-Epitope-Based
Anti-infective Vaccines”), WO2011007359 and EP2453914 (from the years
2009 and 2010) and ”Antigen Specific Multi Epitope Vaccines”
(US20100074925 (claims 39, 57, 58), EP2089423, WO2008035350, CA2665816
and AU2007298494). In these publications Vaxil described ”peptide
vaccines including the signal peptide domain” (Abstract of
US20120177677 as well as claim 29 (”a vaccine comprising a peptide or
a recombinant polypeptide(!) consisting of at least one signal peptide
domain(!) of at least one target protein(!) of a intracellular(!)
pathogen”) and claim 36 (”restriction enzyme sites” were disclosed in
my DE19925052 A1, claims 9, 12 and 20 (for therapeutic use)) and claim
42 of Vaxil’s US20120177677). But as mentioned above these
descriptions of Vaxil (Vaxil BioTherapeutics Ltd. (TASE:VAXL)) are not
new and not inventive because of my DE19951694.
Investors of Vaxil must know this information, because this key
intellectual property of Vaxil can be lost (for example, patents will
not be granted or if granted by errors of examiners, the patents can
be rejected after reexamination with the United States Patent and
Trademark Office (USPTO)), and thus products/product canditates of
Vaxil can not be protected from competitors.

Like Natural Synthetic Diamonds

Alexander Cherkasky

alexcherkasky@googlemail.com


The novel Cherkasky’s synthetic diamonds according to my International
PCT Patent Application WO2012104722 „Novel Cherkasky’s Synthetic
Diamonds and Diamond-Like Materials and Methods and Devices for
Production Thereof”, US Patent Application US20120199792 „Novel
Cherkasky’s synthetic diamonds and diamond-like materials and methods
and devices for production thereof” and German Patent Application
DE102011010422 “Neuartige synthetische Diamanten und diamantartige
Materialien und Verfahren und Vorrichtung zu ihrer kontinuierlichen
Herstellung” (Novel synthetic diamonds and diamond-like materials and
methods and devices for their continuous manufacturing) can be
preferably produced/manufactured by using the High-Pressure
High-Temperature (HPHT)-Technology and can be manufactured
continuously from continuously cultivated or collected and modified
with catalysts and then incinerated biomass, preferably algal biomass
enriched with salts of metal catalysts in order to achieve, to reach
optimal spatial arrangement and even distribution, dispersion of metal
catalysts in the carbon matrix doped with salts/metal catalysis. The
biomass enriched with salts will be incinerated to ash, whereby the
resulting ash can be also additionally enriched with salts (catalyst
metal-halogen-compounds), and this ash will be converted to diamonds
through HPHT treatment/process. The resulting synthetic diamonds are
very near to or similar with the natural diamonds, especially with
natural eclogitic diamonds, where carbon has organic origin i.e.
carbon originates from detritus, i.e. from biomatter.
Thus, colourless, white and coloured synthetic diamonds can be made,
whereby the production process is similar to natural production
process, i.e. natural production process will be “mimicked”. The
structure of natural diamonds and thus physical and especially optical
properties of natural diamonds will be “mimicked”, i.e. copied or
transferred, because metal ions are dispersed or dotted in the carbon
structure and these metal ions, which are doped in a carbon/diamond
host material act as activators or excitable light emitters. These
synthetic diamonds according to my invention comprise the
incorporation of a wide range of dopants (using controlled doping) and
if necessary in high concentrations, thus the resulting synthetic
diamonds are fluorescent and/or phosphorescent.
In current, recent methods, carbon will be firstly purified from
metals and than mixed with metals, but it is not necessary to purify
carbon from metals and than mix it with metals in order to produce
synthetic diamonds.
Thus, this invention allows to increase yield of HPHT-process and to
manufacture large amounts of synthetic diamonds with high quality and
structure and properties like in natural diamonds. It will be also
possible to make novel diamond products.

The World Federation of Diamond Bourses (WFDB) in Antwerp, Belgium
(Ex-President of WFDB Avi Paz, as well as the WFDB-President Ernest
Blom and the Secretary-General of WFDB Rony Unterman) denied and still
deny to publish this information about this my invention of
high-quality like-natural synthetic diamonds on the WFDB website.

Everybody interested in a possible joint commercialization is welcome
to contact me.